Zantac MDL Moves Forward As Parties Select Cases for Bellwether Trials

Zantac MDL Moves Forward As Parties Select Cases for Bellwether Trials

Zantac MDL Moves Forward As Parties Select Cases for Bellwether Trials

On April 1, 2020, the Food and Drug Administration (FDA) requested manufacturers withdraw all prescription and over-the-counter ranitidine (Zantac) drugs from the market. This, after tests, showed the products could contain N-nitrosodimethylamine (NDMA), a potent carcinogen.

Meanwhile, many consumers had already filed Zantac lawsuits, claiming that they had taken the drug for years and were later diagnosed with cancer as a result. In February 2020, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally filed Zantac lawsuits in the U.S. District Court for the Southern District of Florida for consolidated pre-trial proceedings.

Now the judge overseeing the Zantac MDL has ordered the parties to randomly select 200 cases to be part of an initial discovery pool.


About TriMark

TriMark Legal Funding provides non-recourse pre-settlement and post-settlement funding to injured plaintiffs with multidistrict litigation cases nationwide. Call (877) 932-2628 to see if you qualify for funding.

This post originally appeared here: https://newyork.legalexaminer.com/legal/zantac-mdl-moves-forward-as-parties-select-cases-for-bellwether-trials/

Click here to see the full original article.

Still have questions?

Call (877) 932-2628 and speak with one of our legal funding experts.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in plaintiffs’ legal claims. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408